Results 11 to 20 of about 556,908 (299)
Testosterone Patch Increases Sexual Activity and Desire in Surgically Menopausal Women with Hypoactive Sexual Desire Disorder [PDF]
AbstractContext: Hypoactive sexual desire disorder (HSDD) is one of the most common sexual problems reported by women, but few studies have been conducted to evaluate treatments for this condition.Objective: The objective of this study was to evaluate the efficacy and safety of a testosterone patch in surgically menopausal women with HSDD.Design: The ...
James A. Simon+12 more
semanticscholar +4 more sources
Contact allergy to a testosterone patch [PDF]
D.A. Buckley+2 more
semanticscholar +5 more sources
Open-Label Pilot Study of Testosterone Patch Therapy in Men With Opioid-Induced Androgen Deficiency
We conducted a 24-week open-label pilot study of testosterone (T) patch therapy in 23 men with opioid-induced androgen deficiency (OPIAD). The T dosage was 5 mg/day for the first 12 weeks and 7.5 mg/day for the second 12 weeks. Seven subjects discontinued prematurely: 4 for noncompliance, 2 for skin irritation and 1 for hepatitis C treatment.
Henry Daniell+2 more
semanticscholar +5 more sources
ABSTRACT Aim To assess the amount of testosterone transferred from the abdominal application sites of a transdermal testosterone patch and a transdermal testosterone gel to cotton T-shirts worn for 24 hours during each treatment. Methods
Norman A. Mazer+5 more
semanticscholar +5 more sources
The testosterone patch for women [PDF]
Has the FDA discriminated against female sexual dysfunction by not endorsing Procter & Gamble's (P&G) Intrinsa? Has the pendulum swung so far to the right that drugs for sexual medicine receive undue scrutiny? Why is testosterone replacement therapy available for men, but not for women? How should the pharmaceutical industry proceed with future studies?
S A Kingsberg
openaire +4 more sources
Intrinsa: testosterone patch for low sexual desire in women [PDF]
AbstractIntrinsa, a transdermal testosterone patch, is licensed for women with hypoactive sexual desire disorder following bilateral oophorectomy or hysterectomy. Here, Steve Chaplin presents the clinical data relating to its efficacy and adverse effects, and Mr Panay comments on its role in therapy.
Nick Panay, Steve Chaplin
openaire +3 more sources
Local and Systemic Complications of Local Testosterone Patches and Gels
In recent decades, testosterone therapy has gained the attention of many researchers due to the increased demand for this modality worldwide, the increased average age of the different populations, and increased awareness of the potential uses of the modality in clinical settings.
Fahad Ahmed Al-Zahrani+10 more
openalex +4 more sources
ABSTRACT Aim To compare the pharmacokinetics (PK), metabolism, intra- and inter-subject variability of a permeation-enhanced testosterone patch versus a topical testosterone gel. Methods 28 hypogonadal men were treated with a ...
Jerome Fischer+5 more
openaire +4 more sources
Testosterone patch improves ovarian follicular response to gonadotrophins in a patient with Kallmann's syndrome: A Case Report [PDF]
Achieving ovulation in women with Kallmann's syndrome requires both exogenous FSH and LH to successfully stimulate follicular maturation and ovarian steroidogenesis. We present a case of a woman with Kallmann's syndrome, who had poor ovarian response to stimulation by exogenous gonadotrophins.
C. S. Sipe, Bradley J. Van Voorhis
openaire +4 more sources
Double‐blind placebo‐controlled study of testosterone patch therapy on bone turnover in men with borderline hypogonadism [PDF]
SummaryClinical studies suggest there may be a threshold concentration of serum testosterone below which replacement will result in skeletal and psychological benefit. We evaluated the response to testosterone in men with borderline hypogonadism. A randomized double‐blind placebo‐controlled trial in 39 men over age 40 years presenting with sexual ...
Merza, Z.+8 more
openaire +5 more sources